SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $19
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $23 to $19.
Why BridgeBio Pharma Stock Is Shooting Higher
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret.
What Else?
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week
BridgeBio Pharma Highlights Its RAS Precision Oncology Portfolio And Shares Compelling Data From Next-Generation G12C Inhibitor And Novel PI3Kα:RAS Breaker Mechanism At The Fourth RAS Initiative Symposium
- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples
Increase in the ratio of glycosylated αDG to total
BridgeBio Pharma Presents Updated Data From Its BBP-812 Canavan Disease Gene Therapy Program At The 51st Annual Meeting Of The Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease
- Pharmacodynamic data from the first three participants show sustained reductions in N-acetylaspartate (NAA) in
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…